Hugo Cheinquer
YOU?
Author Swipe
View article: REVIRAL: ROADMAP FOR THE ELIMINATION OF VIRAL HEPATITIS IN LATIN AMERICA
REVIRAL: ROADMAP FOR THE ELIMINATION OF VIRAL HEPATITIS IN LATIN AMERICA Open
Introduction and Objectives: Viral hepatitis elimination remains a major challenge in Latin America due to disparities in access to diagnosis, treatment, and follow-up. The REVIRAL study aims to assess disease burden, evaluate healthcare d…
View article: FIBRATES SEEM TO BE EQUALLY EFFECTIVE AS SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS, WITH BIOCHEMICAL RESPONSE PLATEAUING AT 6 MONTHS
FIBRATES SEEM TO BE EQUALLY EFFECTIVE AS SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS, WITH BIOCHEMICAL RESPONSE PLATEAUING AT 6 MONTHS Open
Introduction and Objectives: Approximately 40% of patients with primary biliary cholangitis (PBC) exhibit an incomplete biochemical response to ursodeoxycholic acid (UDCA) and require second-line therapy. Fibrates are widely available in L…
View article: AMA-NEGATIVE PRIMARY BILIARY CHOLANGITIS IN LATIN AMERICA: A DISTINCT SUBSET WITH LOWER TREATMENT RESPONSE
AMA-NEGATIVE PRIMARY BILIARY CHOLANGITIS IN LATIN AMERICA: A DISTINCT SUBSET WITH LOWER TREATMENT RESPONSE Open
Introduction and Objectives: Primary biliary cholangitis (PBC) is an autoimmune cholestatic disease, typically diagnosed by the presence of anti-mitochondrial antibodies (AMA). Whether AMA-negative PBC represents a distinct clinical phenot…
View article: REVIRAL: roadmap for the elimination of viral hepatitis in Latin America
REVIRAL: roadmap for the elimination of viral hepatitis in Latin America Open
The REVIRAL project proposes a comprehensive and tailored strategy for the elimination of viral hepatitis in Latin America, drawing inspiration from successful models in other countries. Despite global advances, the region faces specific b…
View article: Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis Open
Background and Aims The survival outcomes associated with hepatic recompensation in patients with advanced hepatocellular carcinoma (HCC) treated with first‐line systemic therapies remain unclear. We compared survival from the initiation o…
View article: Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies Open
Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization established targets to el…
View article: P-32 ACCESSIBILITY TO SEQUENTIAL SYSTEMIC TREATMENT AFTER TACE: IMPACT ON SURVIVAL IN A LATIN AMERICAN PROSPECTIVE COHORT
P-32 ACCESSIBILITY TO SEQUENTIAL SYSTEMIC TREATMENT AFTER TACE: IMPACT ON SURVIVAL IN A LATIN AMERICAN PROSPECTIVE COHORT Open
Conflict of interest: No Introduction and Objectives: Stopping rules following transarterial chemoembolization (TACE), either tumor progression or “unTACEable” progression are needed. Avoiding liver decompensation after TACE may lead bette…
View article: O3- RECOMPENSATION IN PATIENTS WITH CIRRHOSIS PRIOR TO FIRST LINE SYSTEMIC THERAPY IS ASSOCIATED WITH SIMILAR SURVIVAL OUTCOMES COMPARED TO COMPENSATED CIRRHOSIS
O3- RECOMPENSATION IN PATIENTS WITH CIRRHOSIS PRIOR TO FIRST LINE SYSTEMIC THERAPY IS ASSOCIATED WITH SIMILAR SURVIVAL OUTCOMES COMPARED TO COMPENSATED CIRRHOSIS Open
Conflict of interest: No Introduction and Objectives: The term “recompensation” of cirrhosis was proposed in the latest BAVENO VII, underlying dynamic events and prognosis in cirrhosis. However, there is uncertainty regarding its prognosis…
View article: P-34 ALBUMIN-BILIRUBIN GRADE ANALYSIS OF OVERALL SURVIVAL WITH ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
P-34 ALBUMIN-BILIRUBIN GRADE ANALYSIS OF OVERALL SURVIVAL WITH ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA Open
Conflict of interest: No Introduction and Objectives: Atezolizumab-bevacizumab (atezo-bev) is currently recommended as first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness in patient…
View article: OP-3 ASSESSING TREATMENT ELIGIBILITY EXPANSION UNDER THE 2024 WHO GUIDELINES FOR CHRONIC HEPATITIS B
OP-3 ASSESSING TREATMENT ELIGIBILITY EXPANSION UNDER THE 2024 WHO GUIDELINES FOR CHRONIC HEPATITIS B Open
Conflict of interest: No Introduction and Objectives: The 2024 WHO guidelines for chronic hepatitis B (CHB) aim to expand and simplify treatment eligibility, but these criteria have not been assessed. We aimed to estimate treatment eligibi…
View article: Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update Open
View article: O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION Open
Liver transplantation (LT) is the preferred treatment for early-stage HCC. Despite restrictive criteria (Milan), recurrence is high and negatively impacts on LT survival. This study aimed to evaluate risk factors and prognosis of HCC recur…
View article: O-22 EFFICACY OF ATEZOLIZUMAB BEVACIZUMAB TREATMENT FOR HEPATOCELLULAR CARCINOMA IN REAL-WORLD CLINICAL PRACTICE AT TWO TERTIARY HEALTHCARE CENTERS IN SOUTHERN BRASIL: FIRST INTERIM ANALYSIS
O-22 EFFICACY OF ATEZOLIZUMAB BEVACIZUMAB TREATMENT FOR HEPATOCELLULAR CARCINOMA IN REAL-WORLD CLINICAL PRACTICE AT TWO TERTIARY HEALTHCARE CENTERS IN SOUTHERN BRASIL: FIRST INTERIM ANALYSIS Open
Atezolizumab and bevacizumab (Atez/Bev) are the new standard of care for first-line systemic therapy of hepatocellular carcinoma (HCC). Real-world data on safety and efficacy of Atez/Bev are scarce in Latin America. We aimed to describe sa…
View article: Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals
Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals Open
Among patients with CHC, SVR after DAA was associated with HbA1c reduction, particularly in those with cirrhosis, genotype 3, and age ≤ 60 years.
View article: Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories Open
View article: Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma Open
Clinical characteristics, including early stage detection, and prognosis of post-SVR HCC differed significantly across geographic regions. Surveillance utilization appears to be a high-yield intervention target to improve prognosis among p…
View article: Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC
Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC Open
The complexity of these patients, with one-third presenting liver decompensation after systemic therapies, underlines the need for multidisciplinary team management and the central role of hepatologists.
View article: Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries Open
View article: O-19 COLLABORATIVE CARE TOWARDS MICROELIMINATION OF HEPATITIS C VIRUS IN A DIALYSIS POPULATION IN SOUTHERN BRAZIL
O-19 COLLABORATIVE CARE TOWARDS MICROELIMINATION OF HEPATITIS C VIRUS IN A DIALYSIS POPULATION IN SOUTHERN BRAZIL Open
Introduction and Objectives: Hepatitis C virus (HCV) eradication from dialysis facilities in a community using direct acting antivirals (DAAs) may be achieved more effectively under a collaborative care model, including a network of hepato…
View article: P-33 IMPACT OF SUSTAINED VIROLOGIC RESPONSE ON GLUCOSE PARAMETERS AMONG CHRONIC HEPATITIS C PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS
P-33 IMPACT OF SUSTAINED VIROLOGIC RESPONSE ON GLUCOSE PARAMETERS AMONG CHRONIC HEPATITIS C PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS Open
Introduction and Objectives: Sustained virological response (SVR) of hepatitis C virus (HCV) with direct acting antivirals (DAAs) improve survival and reduces progression to cirrhosis, decompensation and hepatocellular carcinoma. Glucose m…
View article: P-10 PATTERNS OF PROGRESSION AND TREATMENT DISCONTINUATION IN A REAL LIFE LATIN AMERICAN PROSPECTIVE COHORT STUDY OF INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA: SECOND INTERIM ANALYSIS
P-10 PATTERNS OF PROGRESSION AND TREATMENT DISCONTINUATION IN A REAL LIFE LATIN AMERICAN PROSPECTIVE COHORT STUDY OF INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA: SECOND INTERIM ANALYSIS Open
Introduction and Objectives: Previously published regional real-world results of overall survival (OS) in Barcelona Clinic Liver Cancer (BCLC) B and C patients demanded a prospective cohort study nested in a systematic and continuous medic…
View article: OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA
OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA Open
Aproximadamente 1 de cada 4 pacientes con VHC crónico que eran LTFU eran candidatos para recibir tratamiento. Esta estrategia tiene el potencial de ser efectiva y accesible y tiene un impacto significativo en la cascada de atención del VHC.
View article: National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents
National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents Open
The retreatment of patients previously non-responders to DAAs was associated with high rate of SVR in this sample of Brazilian patients. This finding allows us to conclude that the retreatment options available in the public health system …
View article: Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study Open
View article: P-2 HEPATIC STEATOSIS AMONG PEOPLE LIVING WITH HIV IN SOUTHERN BRAZIL: PREVALENCE AND RISK FACTORS
P-2 HEPATIC STEATOSIS AMONG PEOPLE LIVING WITH HIV IN SOUTHERN BRAZIL: PREVALENCE AND RISK FACTORS Open
View article: P-3 IMPACT OF THE SUSTAINED VIROLOGICAL RESPONSE ON THE GLUCOSE METABOLISM IN PATIENTS WITH HEPATITIS C
P-3 IMPACT OF THE SUSTAINED VIROLOGICAL RESPONSE ON THE GLUCOSE METABOLISM IN PATIENTS WITH HEPATITIS C Open
Introduction: Hepatitis C (HCV) is a systemic disease with hepatic and extrahepatic repercussions, its association with some diseases, such as hepatocellular carcinoma is well documented, however its relationship with glucose metabolism is…
View article: ‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant
‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant Open
All-oral, interferon-free therapy with DAAs for chronic HCV after kidney transplantation was effective and well-tolerated in a 'real-life' clinical setting. Identical results have been observed in patients with intact kidneys or advanced c…
View article: Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil Open
View article: Hepatic steatosis among people living with HIV in Southern Brazil: prevalence and risk factors
Hepatic steatosis among people living with HIV in Southern Brazil: prevalence and risk factors Open
View article: HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America
HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America Open